These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33172606)

  • 1. IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment.
    Li Q; Liu J; Fan H; Shi L; Deng Y; Zhao L; Xiang M; Xu Y; Jiang X; Wang G; Wang L; Wang Z
    Biomaterials; 2021 Feb; 269():120388. PubMed ID: 33172606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymeric IDO inhibitor based on poly(ethylene glycol)-
    Liu Y; Xie J; Zhao X; Zhang Y; Zhong Z; Deng C
    Biomater Sci; 2022 Sep; 10(19):5731-5743. PubMed ID: 36039890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer.
    Hu C; Liu Y; Cao W; Li N; Gao S; Wang Z; Gu F
    Int J Nanomedicine; 2024; 19():507-526. PubMed ID: 38260240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Codelivered Chemotherapeutic Doxorubicin
    Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
    ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
    Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
    Soliman H; Mediavilla-Varela M; Antonia S
    Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
    Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
    Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
    Zang X; Song J; Yi X; Piyu J
    J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy.
    Wang X; Yan B; Li H; Yuan J; Guo J; Wang S; Dai P; Liu X
    ACS Appl Mater Interfaces; 2024 Jun; 16(24):30671-30684. PubMed ID: 38843203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-modulation of tumor and tumor draining lymph nodes through enhanced immunogenic chemotherapy by nano-complexed hyaluronic acid/polyvinyl alcohol microneedle.
    Shi Y; Yu M; Qiu K; Kong T; Guo C; Zhang W; Chen D; Kong M
    Carbohydr Polym; 2024 Feb; 325():121491. PubMed ID: 38008469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.
    Munn DH; Sharma MD; Johnson TS; Rodriguez P
    Cancer Immunol Immunother; 2017 Aug; 66(8):1049-1058. PubMed ID: 28488123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Microenvironment-Specific Driven Nanoagents for Synergistic Mitochondria Damage-Related Immunogenic Cell Death and Alleviated Immunosuppression.
    Qian Y; Chen W; Wang M; Xie Y; Qiao L; Sun Q; Gao M; Li C
    Small Methods; 2024 Jul; 8(7):e2301231. PubMed ID: 38126694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate.
    Lu Y; Xu F; Wang Y; Shi C; Sha Y; He G; Yao Q; Shao K; Sun W; Du J; Fan J; Peng X
    Biomaterials; 2021 Nov; 278():121167. PubMed ID: 34624752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
    Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
    Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
    Johnson TS; Mcgaha T; Munn DH
    Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
    Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J
    J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.